The Canadian bureaucrat who wrote the policy on mandatory vaccination for travel and transportation thought Canada would be leading the way with this measure, but instead it remained an outlier, court documents reveal.
In a briefing prepared for Transport Minister Omar Alghabra before the mandate came into force in late October 2021, the policy was presented as a “world-leading vaccination requirement for travel.”
The Oct. 2 brief titled “Implementing a Vaccine Mandate for the Transportation Sector” was prepared by Jennifer Little, director general of the COVID Recovery Team at Transport Canada.
Little, who submitted an affidavit in April, was cross-examined in June as a witness supporting the government in its defence of four lawsuits challenging the travel vaccine mandate.
“Who came up with this? Is this something you stated?” lawyer Sam Presvelos asked Little regarding the “world-leading” designation.
“Well, it was certainly part of the analysis,” she answered. “As we were working through this in terms of the scope of what we are describing in scoping out a policy at that time, it situated Canada as quite forward-leading in terms of vaccination mandates for the sector.”
“Don’t you think that giving no alternative to leave the country for five million of your citizens ... makes your mandate much more than slightly stronger?” asked lawyer and applicant Nabil Belkacem.
“I agree that it is a strong mandate,” replied Little.
“I’m not aware of any that require them domestically among the G7,” she said, adding that some have border requirements.
The Liberal government suspended vaccine mandates for domestic travel and the public sector on June 20, while warning that the mandates could be brought back depending on circumstances.
Little testified that the government had no criteria in place to determine when the mandates could be lifted.
Waning ProtectionCourt documents show that the government was aware around late December to early January that two doses of the mRNA vaccine would provide little protection against COVID-19 infection.
“I do remember that it became clear to us that two doses or doses that were given several months prior were less protective,” said Dr. Eleni Galanis, director general of the Centre for Integrated Risk Assessment at the Public Health Agency of Canada (PHAC), during cross-examination on June 23.
On Feb. 28, PHAC released the document “Vaccine science to inform COVID-19 vaccination planning and policy (2.0).”
According to Little’s affidavit, the document said that for the Omicron variant, “vaccine effectiveness against infection, symptomatic disease, and transmission with two doses was initially ~<50 to 60%, but waned over time to near zero after six months.”